AbCellera Biologics (NASDAQ:ABCL) Announces Earnings Results, Beats Estimates By $0.04 EPS

AbCellera Biologics (NASDAQ:ABCL) posted its quarterly earnings data on Monday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.04, FiscalAI reports. The company had revenue of $10.64 million during the quarter, compared to analysts’ expectations of $8.41 million. AbCellera Biologics had a negative return on equity of 17.49% and a negative net margin of 248.83%. During the same quarter in the previous year, the business earned ($0.19) EPS.

Here are the key takeaways from AbCellera Biologics’ conference call:

• AbCellera reported strong four-week Phase II results for ABCL635, with an 83% reduction in daily moderate-to-severe hot flashes versus 33% on placebo, and no clear gastrointestinal or liver-toxicity signal. The company cautioned that the study assessed a single dose and that comparisons with other treatments are cross-trial.
• The company plans to advance ABCL635 into late-stage development in 2027 and expects to release 12-week and open-label extension data in early 2027. It also plans to study the drug for treatment-related hot flashes in breast and prostate cancer patients, while a longer-acting follow-on, ABCL992, entered IND-enabling work.
• After completing an oversubscribed $200 million equity raise, AbCellera reported more than $790 million in cash and marketable securities and over $890 million in available liquidity including committed government funding. Management said it has funding for at least three years of pipeline investment.
• AbCellera added three programs—ABCL992, an oncology program, and an ion-channel-targeting antibody—and said ABCL688 and ABCL386 remain in IND-enabling work, with both potentially entering clinical trials in 2027.
• Despite favorable Phase I tolerability and pharmacokinetic results for ABCL575, AbCellera does not plan to advance it beyond Phase I, citing setbacks for other drugs targeting the OX40/OX40L pathway.

AbCellera Biologics Price Performance

Shares of AbCellera Biologics stock opened at $12.50 on Tuesday. AbCellera Biologics has a 1 year low of $2.74 and a 1 year high of $15.02. The firm’s 50-day moving average is $12.30 and its two-hundred day moving average is $7.08. The stock has a market cap of $3.83 billion, a price-to-earnings ratio of -23.15 and a beta of 1.59.

AbCellera Biologics News Summary

Here are the key news stories impacting AbCellera Biologics this week:

• Positive Sentiment: Q3 revenue was $10.64 million, above the roughly $8.4 million consensus estimate. The loss of $0.13 per share was also narrower than estimates of $0.17–$0.18 and the $0.19 loss a year earlier. Zacks Q3 results article
• Negative Sentiment: Despite beating estimates, ABCL continued to post substantial losses: its reported net margin was -248.83%, and return on equity was -17.49%. The quarterly improvement does not yet demonstrate that the business has reached profitability. MarketScreener earnings report

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ABCL shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of AbCellera Biologics in a research report on Thursday, October 15th. Truist Financial upped their price target on shares of AbCellera Biologics from $12.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. assumed coverage on shares of AbCellera Biologics in a research note on Tuesday, September 29th. They set an “overweight” rating and a $17.00 price target for the company. Jefferies Financial Group started coverage on AbCellera Biologics in a report on Friday, October 30th. They issued a “buy” rating and a $21.00 price target for the company. Finally, Cantor Fitzgerald raised their price objective on AbCellera Biologics from $11.00 to $12.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $15.78.

About AbCellera Biologics

AbCellera Biologics Inc is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease.

The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.

Founded in 2012, AbCellera has collaborated with global partners, including Eli Lilly, on antibody treatments for COVID-19.